From data to clinical decision: Optimization of monoclonal antibody dosing in inflammatory bowel diseases
Monoclonal antibodies (mAbs) are key therapies for moderate-to-severe inflammatory bowel disease (IBD). However, substantial interand intraindividual pharmacokinetic variability often leads to suboptimal treatment outcomes. Reactive therapeutic drug monitoring (TDM) is currently recommended, particularly for anti-TNF t...